arsenic trioxide has been researched along with ganciclovir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Block, GJ; Esteves, KC; Flemington, EK; Lasky, JA; Lin, Z; Shan, B; Sides, MD | 1 |
| Flemington, EK; Lasky, JA; Lin, Z; Luo, F; Sides, MD; Sosulski, ML | 1 |
1 review(s) available for arsenic trioxide and ganciclovir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for arsenic trioxide and ganciclovir
| Article | Year |
|---|---|
Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.
Topics: Antiviral Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Viral; Epithelial Cells; Ganciclovir; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins; Up-Regulation; Viral Matrix Proteins | 2011 |
Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Disease Models, Animal; Drug Therapy, Combination; Ganciclovir; Heterografts; Humans; Mice; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oxides; Treatment Outcome; Tumor Burden | 2013 |